In FY24, our Group Scientific Advisory Committee, consisting of Scientific Directors from Australia and Asia, has concentrated on delivering top-tier success rates for our patients. This has been achieved through our unwavering commitment to scientific excellence, researching and implementing new technologies, and translating novel research findings into clinical practice.

Key highlights for FY24 include:

Completion of the three-year phased Embryoscope+ timelapse technology rollout across Monash IVF Group resulting in 18 Embryoscope+ incubators being installed across 11 sites. In addition, the introduction of single-step embryo culture medium containing antioxidants across all our sites has maximised the utility of the Embryoscopes, reduced embryo handling and risk associated with the culture system, and further improved our IVF success rates.

We have formulated a unique partnership with Symex to develop a wearable realtime fertility hormone monitoring system to replace the existing time-consuming and painful regular blood samples patients undertake during their ART cycle. Validation of this ground-breaking technology would revolutionise patient treatment, reduce cost and provide more convenience for patients by replacing the need for clinic visits. Monash IVF Group became an early investor and holds future equity in Symex Labs, as well as an exclusivity agreement with respect to its clinical partnership with the company.

The new Monash IVF Group embryology training program was launched, providing a best in class standard for embryology training and capability. This further contributes to The Monash Way to provide the highest quality embryology service to our patients and clinicians.

Monash IVF Group has distinguished itself by publishing 46 peer-reviewed studies in premier fertility journals and presenting 22 research abstracts and invited lectures across all departments (embryology, andrology, genetics and nursing) at esteemed international and national conference. These activities resulted in Monash IVF Group and receiving awards in recognition of research excellence. These collective scientific accomplishments underscore our unwavering commitment to research and evidence-based practice, propelling superior patient care and outcomes.

Monash IVF Group Science remains at the forefront of assisted reproductive technology innovation and is committed to continuously improving our patient outcomes and success rates.